FindTrial
Sign In

Letrozole adjuvant therapy duration (LEAD)study: standard versus long treatment. A phase III study in postmenopausal women with early breast cancer

Letrozole adjuvant therapy duration (LEAD)study: standard versus long treatment. A phase III study in postmenopausal women with early breast cancer

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-001212-44-IT
Enrollment
Unknown
Registered
2005-09-02
Start date
2005-07-27
Completion date
Unknown
Last updated
2013-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adjuvant therapy with letrozole after 2 or 3 years of tamoxifen for early breast cancer MedDRA version: 14.1 Level: PT Classification code 10057654 Term: Breast cancer female System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Interventions

Trade Name: FEMARA*30CPR RIV 2,5MG Pharmaceutical Form: Tablet CAS Number: 112809-51-5 Concentration unit: mg milligram(s) Concentration number: 2.5-

Sponsors

CONSORZIO ONCOTECH
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026